News Headlines http://www.cellmid.com.au/ News Headlines. For all the news, visit http://www.cellmid.com.au/ en-au SYDNEY, Thursday 02 August 2018 http://www.proactiveinvestors.com.au/companies/stocktube/10004/cellmid-expanding-products-portfolio-and-markets-and-approaching-profitablity-10004.html Cellmid raises the bar with global expansion, investment & market reach on @proactive_au b29ceba2-7a80-418d-b64a-a54aa3960ae4 Thursday, 2 August 2018 SYDNEY, Wednesday 11 July 2018 http://www.managemysite.com.au/sitemedia/w3svc921/uploads/documents/2018%2007%2011%20cellmid%20update%20on%20distribution%20of%20evolis.pdf Cellmid Updates on Distribution of évolis 75a943d9-b90d-4256-af13-b184b2c1b9e7 Wednesday, 11 July 2018 SYDNEY, Wednesday 04 April 2018 http://www.cellmid.com.au/content_common/ns-cellmid-20fillerina-20announcement.seo Cellmid Limited (ASX:CDY) (the Company) advises that it has entered into an agreement with Labo International S.r.l to undertake the exclusive distribution of Fillerina®, a market leading Swiss anti-aging skincare brand, in Australia and New Zealand for up to an initial five years. 3e45fe12-7ca4-4e7a-82f2-6d1de62d42f9 Wednesday, 4 April 2018 SYDNEY, Monday 21 November 2016 http://www.cellmid.com.au/content_common/ns-lodge-partners-research-cellmid.seo "Hair growth equals Sales Growth equals Share Price Growth" Lodge Partners Analyst Marc Sinatra reports on Cellmid Limited f98fec69-ab11-445e-a274-232a9876c51f Monday, 21 November 2016 SYDNEY, Monday 12 December 2016 http://www.cellmid.com.au/content_common/ns-pacific-edge-update-2016.seo Cellmid Limited (ASX: CDY) provides this update to shareholders on recent developments regarding its midkine diagnostic license to Pacific Edge Biotechnology Limited (Pacific Edge). 16562bc1-d056-45a8-aaec-e84945dfd548 Monday, 12 December 2016 SYDNEY, Friday 03 August 2018 https://www.afr.com/business/health/former-coles-ceo-dennis-eck-backs-cellmids-chinese-phrama-push-with-9-million-20180801-h13g73 Former Coles CEO Dennis Eck backs Cellmid's Chinese pharma push 08886946-1183-46fb-ac2d-db1f8ab26880 Friday, 3 August 2018 SYDNEY, Friday 31 July 2018 http://www.managemysite.com.au/sitemedia/w3svc921/uploads/documents/2018%2007%2031%20cellmid%20raised%20$9m%20via%20share%20placement.pdf Cellmid share placement raises $9.0 Million 3a80b2ee-ff68-4b61-b6fd-b73443e2987d Tuesday, 31 July 2018 SYDNEY, Monday 9 April 2018 http://www.cellmid.com.au/content_common/ns-cellmid-convening-global-meeting-of-midkine-researchers-in-germany.seo Cellmid Limited (ASX:CDY) will be convening the 5th Midkine Symposium in Munich, Germany between 3rd and 5th May 2018. 6282afc4-074c-48f8-91df-499ef5b24ec0 Monday, 9 April 2018 SYDNEY, Friday 27 April 2018 http://www.cellmid.com.au/content_common/ns-the-australian-interviews-dennis-eck.seo The Weekend Australian Interviews Cellmid Director Dennis Eck 499f7dfe-fa5e-4566-a2b9-8ead1c1a5ffd Friday, 27 April 2018 SYDNEY, Tuesday 07 February 2017 http://www.cellmid.com.au/content_common/ns-eu-patent-allowance-mk-alopecia-2017.seo Cellmid Limited (ASX: CDY) is pleased to advise that the European Patent Office has issued Notice of Allowance for the patent application number 11746751.4 entitled “Method of Treatment or Prevention of Hair Loss or for Enhancement of Hair Growth” (midkine or MK alopecia patent). 541bdeeb-97ac-4781-9a75-c16019e4b261 Tuesday, 7 February 2017 SYDNEY, Thursday 02 March 2017 http://www.cellmid.com.au/content_common/ns-fgf5-study-published-2017.seo Cellmid Limited (ASX: CDY) is pleased to advise that a manuscript describing the screening approach and clinical study carried out by Cellmid’s wholly owned subsidiary, Advangen Limited, has been published in the journal Clinical, Cosmetic, and Investigational Dermatology 10: 71-85. 27 Feb 2017. abf58731-9c8c-4697-9c67-34557215214b Thursday, 2 March 2017 SYDNEY, Wednesday 02 May 2018 http://www.cellmid.com.au/content_common/ns-cellmid-inks-deal-with-chinas-fukangren-bio-pharm.seo Australia based Cellmid has recently announced that its wholly owned subsidiary Advangen Limited (“Advangen”) has entered into an exclusive agreement with Beijing Fukangren Bio-pharm Techto distribute its évolis anti-aging hair care products in the Peoples Republic of China. 554ed0c3-833e-4863-9473-b000a755e7eb Wednesday, 2 May 2018 SYDNEY, Tuesday 31 January 2017 http://www.cellmid.com.au/content_common/ns-usa-midkine-alopecia-patent-allowed.seo Cellmid Limited (ASX: CDY) is pleased to advise that the US Patent and Trademark Office has issued Notice of Allowance for the patent application number 14/464,358 entitled “Method of Treatment or Prevention of Hair Loss or for Enhancement of Hair Growth” (midkine or MK alopecia patent). f8f3fe68-08dd-4aae-be49-195e6170162b Tuesday, 31 January 2017 SYDNEY, Tuesday 24 April 2018 http://www.cellmid.com.au/content_common/ns-details.seo Proven strategies across the marketing spectrum for businesses big and small, delivered by Peter Applebaum and a team of experts. Featuring Maria Halasz. e6ab071e-3ae2-448f-b934-2a5b9a150203 Tuesday, 24 April 2018